Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Closed 01-20 16:00:00 EST

324.08

+6.83

+2.15%

盘后324.08

+0.000.00%

18:08 EST

High326.06	Low307.20	Vol576.98K
Open307.20	D1 Closing317.25	Amplitude5.94%
Mkt Cap8.88B	Tradable Cap7.43B	Total Shares27.41M
T/O184.32M	T/O Rate2.52%	Tradable Shares22.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":324.08,"timestamp":1768942800000,"preClose":317.25,"halted":0,"volume":576984,"hourTrading":{"tag":"盘后","latestPrice":324.08,"preClose":324.08,"latestTime":"18:08 EST","volume":76615,"amount":24829237.75,"timestamp":1768950529519,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0215287628053585,"floatShares":22922500,"shares":27407092,"eps":-12.922727,"marketStatus":"Closed","change":6.83,"latestTime":"01-20 16:00:00 EST","open":307.2,"high":326.06,"low":307.2,"amount":184315202.01479998,"amplitude":0.059448,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768986000000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":317.25,"preHourTrading":{"tag":"盘前","latestPrice":309,"preClose":317.25,"latestTime":"09:29 EST","volume":269,"amount":83113.7908,"timestamp":1768919399904,"change":-8.25,"changeRate":-0.026005,"amplitude":0.034673},"postHourTrading":{"tag":"盘后","latestPrice":324.08,"preClose":324.08,"latestTime":"18:08 EST","volume":76615,"amount":24829237.75,"timestamp":1768950529519,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.940696,"impliedVol":0.7402,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/PRAX/tweets","defaultTab":"tweets","newsList":[{"id":"2603581716","title":"Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603581716","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603581716?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:30","pubTimestamp":1768339820,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky, a prominent neurologist and epilepsy expert, will guide clinical strategy and global medical affairs as the company advances its CNS medicine portfolio. He will report to Steven Petrou, President of Research and Development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL91DBXy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE0002141913.USD","IE0009355771.USD","IE00BGHQF748.EUR","IE00B2B36J28.USD","BK4585","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","LU2210150020.SGD","PRAX","IE00BKPKM429.USD","BK4139","SG9999014013.SGD","LU0314104364.USD","LU0109394709.USD","IE00BJT1NW94.SGD","NDAQ","IE00BJJMRZ35.SGD","BK4112","SG9999014005.SGD","LU0320765992.SGD","BK4588","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2603465819","title":"Praxis Precision Medicines Appoints Global Epilepsy Leader DR. Orrin Devinsky as Head of Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603465819","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603465819?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:30","pubTimestamp":1768339802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8SGB4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4139","PRAX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2603524896","title":"Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603524896","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603524896?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:45","pubTimestamp":1768257909,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Jeffrey B. Kindler as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9Qz7fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PRAX","LU0320765992.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2602545146","title":"Praxis Precision price target raised to $95 from $83 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545146?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:13","pubTimestamp":1768227195,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico raised the firm’s price target on Praxis Precision (PRAX) to $95 from $83 and keeps an Underperform rating on the share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-95-from-83-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-95-from-83-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","PRAX","LU0889565916.HKD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"2602028543","title":"Praxis Precision Med Is Maintained at Underperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2602028543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602028543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 09:02 ET (14:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","PRAX","LU0889565916.HKD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"2602510290","title":"Praxis Precision Medicines Highlights CNS Drug Pipeline and Commercial Strategy in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510290","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510290?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:15","pubTimestamp":1768223734,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. provided an update on its late-stage pipeline focused on central nervous system  disorders. The presentation highlighted key therapies including ulixacaltamide for essential tremor, relutrigine for developmental and epileptic encephalopathies , vormatrigine for focal and generalized epilepsy, and elsunersen for SCN2A-related DEE. The company reported positive clinical trial results, Breakthrough Therapy Designation status for some candidates, and outlined plans for upcoming New Drug Application  submissions. Praxis estimated significant commercial potential across its portfolio, referencing high unmet need in targeted indications and drawing comparisons to current market pricing for similar therapies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLccY37N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PRAX","LU0320765992.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2602510138","title":"BRIEF-Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-Dees","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510138?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:09","pubTimestamp":1768223359,"startTime":"0","endTime":"0","summary":"BRIEF-Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-DeesJan 12 (Reuters) - Praxis Precision Medicines...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4139","PRAX","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2602151067","title":"Praxis Precision Medicines Inc - Two Nda Submissions Expected by Mid-Feb 2026 for Ulixacaltamide in Essential Tremor & Relutrigine in Scn2a/8a-Dees","url":"https://stock-news.laohu8.com/highlight/detail?id=2602151067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602151067?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:06","pubTimestamp":1768223181,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4139","IE00BJT1NW94.SGD","IE0009355771.USD","PRAX","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602840510","title":"Praxis Precision Medicines Appoints Kinder and Arbuckle to Board and Promotes Sniecinski and Petrou to Leadership Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2602840510","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602840510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222862,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has announced changes to its leadership team, appointing Jeffrey B. Kinder and Stuart Arbuckle to its Board of Directors. Additionally, Megan Sniecinski has been promoted to Chief Operating Officer, and Dr. Steven Petrou has been named President of Research & Development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbKvGJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","SG9999014005.SGD","BK4585","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","IE0009355771.USD","LU2210150020.SGD","LU0109394709.USD","BK4588","LU0314104364.USD","BK4139","SG9999014039.USD","PRAX","BK4112","IE00B3QW5Z07.USD","IE00BJT1NW94.SGD","LU2210149790.SGD","IE00B2B36J28.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE0002141913.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BGHQF748.EUR","SG9999014021.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2602514000","title":"Wedbush Raises Price Target on Praxis Precision Medicines to $95 From $83, Keeps Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514000","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514000?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:11","pubTimestamp":1768219877,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $461.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"gpt_icon":0},{"id":"2602301102","title":"Praxis Precision Medicines Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Megan Sniecinski","url":"https://stock-news.laohu8.com/highlight/detail?id=2602301102","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602301102?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:37","pubTimestamp":1767994668,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Megan Sniecinski, the company's Chief Operating Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL9F7T3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Praxis Precision Medicines Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Megan Sniecinski","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","LU0109394709.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2602092223","title":"Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2602092223","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602092223?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:01","pubTimestamp":1767992466,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has granted restricted stock unit awards covering a total of 434 shares of its common stock to three new non-executive employees. These awards were made under the company's 2024 Inducement Plan. The restricted stock units will vest in four equal annual installments, contingent on continued employment with Praxis on each vesting date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL2ty3Hq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","LU2210149790.SGD","SG9999014039.USD","BK4139","SG9999014005.SGD","NDAQ","IE00B4R5TH58.HKD","PRAX","BK4112","BK4585","LU0889565916.HKD","LU0320765992.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","LU0109394709.USD","IE00BKPKM429.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2602309243","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602309243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602309243?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:01","pubTimestamp":1767992460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUALDS4G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRAX","LU0109394709.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602320264","title":"High Growth Tech Stocks In The US For January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602320264","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602320264?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:08","pubTimestamp":1767956897,"startTime":"0","endTime":"0","summary":"As we enter January 2026, the U.S. stock market is experiencing a mixed performance with the Dow Jones Industrial Average showing gains while the tech-heavy Nasdaq has faced challenges due to a downturn in data-storage shares. In this fluctuating environment, identifying high growth tech stocks requires careful consideration of their resilience and potential for innovation amidst broader economic indicators and market sentiment.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-frsh/freshworks/news/high-growth-tech-stocks-in-the-us-for-january-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-frsh/freshworks/news/high-growth-tech-stocks-in-the-us-for-january-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","PRAX","BK4023","FRSH","IE0009355771.USD","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0053671581.USD","BK4139","BK4585","LU0109394709.USD","BK4588","PTGX"],"gpt_icon":0},{"id":"2602328380","title":"How Praxis’s Big Equity Raise, Ulixacaltamide Breakthrough Status And Board Shake-Up At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2602328380","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602328380?lang=en_us&edition=fundamental","pubTime":"2026-01-09 14:24","pubTimestamp":1767939871,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines recently priced and completed a very large follow-on equity offering of 2,212,000 common shares at US$260 each, raising about US$575.12 million to support its central nervous system pipeline, while also securing FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor and advancing toward an NDA filing in early 2026.\nOn top of this capital raise, Praxis reshaped its leadership bench by adding former Pfizer CEO Jeffrey Kindler and veteran...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/how-praxiss-big-equity-raise-ulixacaltamide-breakthrough-sta","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/how-praxiss-big-equity-raise-ulixacaltamide-breakthrough-sta","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","BK4585","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4588","BK4139","EQR","PRAX"],"gpt_icon":0},{"id":"2602315874","title":"Praxis Precision names Megan Sniecinski as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602315874","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602315874?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:50","pubTimestamp":1767909053,"startTime":"0","endTime":"0","summary":"Praxis Precision (PRAX) Medicines announced the appointment of Jeffrey Kindler and Stuart Arbuckle to its board of directors, and the promotions of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-names-megan-sniecinski-as-coo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-names-megan-sniecinski-as-coo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU1992135399.USD","BK4588","LU2272731782.SGD","BK4585","PRAX","LU0320765992.SGD","BK4139","LU0109394709.USD","LU1992135472.HKD","GB00BDT5M118.USD","LU2211815571.USD","LU2272731600.USD","BK4198","COO"],"gpt_icon":0},{"id":"2602497313","title":"Praxis Precision Medicines Appoints Kindler and Arbuckle to Board and Promotes Sniecinski and Petrou","url":"https://stock-news.laohu8.com/highlight/detail?id=2602497313","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602497313?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:45","pubTimestamp":1767908709,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors. Megan Sniecinski has been promoted to Chief Operating Officer, and Dr. Steven Petrou has been promoted to President of Research & Development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL3QjxvW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0320765992.SGD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0109394709.USD","LU0314104364.USD","LU0889565916.HKD","NDAQ","BK4585","PRAX","BK4112","BK4139","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2602460313","title":"Press Release: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2602460313","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602460313?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:45","pubTimestamp":1767908700,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 08, 2026  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation--inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development.Stuart Arbuckle is a highly accomplished executive with deep experience leading global commercial success at biopharmaceutical organizations. He spent 13 years at Vertex Pharmaceuticals, most recently serving as Executive Vice President and Chief Operating Officer, where he oversaw, among many areas, Vertex's global commercial, human resources and program, and portfolio management and played a pivotal role in the company's global growth and scale. Prior to Vertex, Mr. Arbuckle held multiple commercial ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4099","ASO","BK4139","BK4588","BK4604","CNS","LU0109394709.USD","LU0889565916.HKD","BK4200","PRAX","BK4561","TM","LU0320765992.SGD","BK4555","BK4585","03160"],"gpt_icon":0},{"id":"2601383269","title":"BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2601383269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601383269?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:51","pubTimestamp":1767811889,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe'sEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y80LY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKR","HSY","PENG","VTYX","HUM","IONS","CL","CDE","MTYY","GE","AIR","CALM","AJG","VERA","NVDA","DECK","RZLT","UNP","LMT","BA","LNG","EXE","W","HAL","LOW","SLB","LBRT","NEM","UNF","ACI","GLUE","PRAX","TXR","CRNX","RTX","ARWR","APOG","HL","COMP","FSLR","MTB"],"gpt_icon":1},{"id":"2601809779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601809779?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:26","pubTimestamp":1767795994,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine FoodsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y80LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSY","CALM","SMST","APOG","UNP","DECK","PRAX","BAC","CRNX","MSTY.UK","IMST","CDE","COMP","MST","MSST","NEM","SMI3.UK","TXR","MTB","MSCI","RTX","PENG","LMI3.UK","LMT","VTYX","AIR","09799","VERA","FSLR","MSTY","RZLT","MSII","HOUS","MSTK","07399","GLUE","HUM","ARWR","CL","AJG","WNTR","HL"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.0998},{"period":"1month","weight":0.1933},{"period":"3month","weight":0.6698},{"period":"6month","weight":4.8914},{"period":"1year","weight":3.516},{"period":"ytd","weight":0.0764}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.300165},{"month":2,"riseRate":0.2,"avgChangeRate":-0.21435},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}